EMA Starts ‘Rolling Review’ Of AstraZeneca’s COVID-19 Vaccine
The European Medicines Agency says its rolling review tool should speed up the evaluation of AstraZeneca’s COVID-19 vaccine.
You may also be interested in...
The European Medicines Agency will continue working over the Christmas period so that it can complete its assessment of the newly filed marketing applications for BioNTech/Pfizer’s and Moderna’s COVID-19 vaccines as soon possible.
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.
Russia is planning to register a second COVID-19 vaccine this month, while the UK is ramping up its manufacturing capacity for vaccines and therapeutics.